Hemiplegic migraine

Global Migraine Epidemiology Forecast to 2030 - Key Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 12, 2021
Health, Other Health, Headaches, Migraine, Channelopathies, Rare diseases, Epidemiology, Branches of biology, Clinical medicine, Medicine, Hemiplegic migraine

b'The "Migraine - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nThis report delivers an in-depth understanding of the migraine, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.\nThe disease epidemiology covered in the report provides historical as well as forecasted Migraine epidemiology segmented as the Total Prevalent Cases of Migraine, Severity-specific cases of Migraine, Gender-specific cases of Migraine, Diagnosed Cases of Episodic and Chronic Migraine.

Key Points: 
  • b'The "Migraine - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nThis report delivers an in-depth understanding of the migraine, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.\nThe disease epidemiology covered in the report provides historical as well as forecasted Migraine epidemiology segmented as the Total Prevalent Cases of Migraine, Severity-specific cases of Migraine, Gender-specific cases of Migraine, Diagnosed Cases of Episodic and Chronic Migraine.
  • The opinion helps understand the total patient population and current treatment pattern.
  • This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.\nWhat will be the growth opportunities in the 7MM concerning the patient population about migraine?\nWhat are the key findings of Migraine epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021-2030)?\nWhat are the disease risk, burden, and unmet needs of migraine?\nWhat are the currently available treatments for migraine?\nQuantify patient populations in the global Migraine market to improve product design, pricing, and launch plans\nThe Migraine Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies.
  • Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources\n'

Upsher-Smith Offers Help To People With Migraines During National Migraine And Headache Awareness Month

Retrieved on: 
Tuesday, June 23, 2020
Headaches, Clinical medicine, Medicine, Migraine, Pain, Headache, Medication overuse headache, Upsher-Smith Laboratories, Hemiplegic migraine, NIH classification of headaches

MAPLE GROVE, Minn., June 23, 2020 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced its continued commitment to people who suffer from migraines during National Migraine & Headache Awareness Month (MHAM).

Key Points: 
  • MAPLE GROVE, Minn., June 23, 2020 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced its continued commitment to people who suffer from migraines during National Migraine & Headache Awareness Month (MHAM).
  • Supported by Upsher-Smith's Access Pathways Program, eligible patients pay $0 Per Prescription* for their migraine medication with the Platinum Pass Savings Card.
  • Do not use TOSYMRA if you have:
    narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
    hemiplegic migraines or basilar migraines.
  • Some people who use too much migraine medicine, such as TOSYMRA, for 10 or more days each month may have worse headaches (medication overuse headache).

Global Migraine Disease Epidemiology 2019-2038: Revalent Population is Likely to Remain Stable

Retrieved on: 
Tuesday, June 18, 2019
Clinical medicine, Medicine, Organ systems, Migraine, Headache, ICHD classification and diagnosis of migraine, Hemiplegic migraine

DUBLIN, June 18, 2019 /PRNewswire/ -- The "Migraine Disease Coverage Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 18, 2019 /PRNewswire/ -- The "Migraine Disease Coverage Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Migraine is a common, disabling, and recurring neurological disorder characterized by severe headache co-occurring with nausea, vomiting, and other symptoms, the duration of which can range from hours to days.
  • Causes of migraine are incompletely understood, but genetics and lifestyle are both involved in migraine and progression of migraine severity.
  • The prevalent population of this common condition is likely to remain stable over the forecast period.